A successful infection involves virus entry into the cell; uncoating, expression, and replication of the genome; assembly and release of infectious virus particles; and defense against specific and non-specific host immune mechanisms. Combined genetic, biochemical, electron microscopic, and immunologic approaches are being used to investigate these complex processes. During the past year we continued work on the assembly of vaccinia virus. We identified a protein component of the intracellular mature vaccinia virion membrane that is a target of a potent neutralizing monoclonal antibody. By immunofluorescent and electron microscopic analysis, the antibody was found to stain intracytoplasmic viral factories, virion membranes in cell sections and the surface of negatively stained purified virions. The antigen, which is synthesized at late times in infection, has apparent molecular masses of 25 kDa and 29 kDa under non-reducing and reducing conditions, respectively. Although the N-terminus of the immunoaffinity purified protein was blocked, sequence analysis of trypic peptides revealed that the antigen was identical to the myristylated protein encoded by the LIR open reading frame. Validation of this genetic assignment was provided by the ability of the antibody to immunoprecipitate a [3H]myristic acid-labeled product of the expected molecular weight from infected cells. We expressed in Escherichia coli the vaccinia virus gene for a protein similar to vertebrate profilins, purified the recombinant viral profilin, and characterized it. The viral profilin differed from the vertebrate homolog by having a higher affinity for polyphosphoinositides than actin suggesting that it may have a primary role in phosphoinositide metablolism.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Intramural Research (Z01)
Project #
1Z01AI000539-08
Application #
5200498
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
8
Fiscal Year
1995
Total Cost
Indirect Cost
City
State
Country
United States
Zip Code
Wagenaar, Timothy R; Moss, Bernard (2009) Expression of the A56 and K2 proteins is sufficient to inhibit vaccinia virus entry and cell fusion. J Virol 83:1546-54
Resch, Wolfgang; Weisberg, Andrea S; Moss, Bernard (2009) Expression of the highly conserved vaccinia virus E6 protein is required for virion morphogenesis. Virology 386:478-85
Nelson, Gretchen E; Wagenaar, Timothy R; Moss, Bernard (2008) A conserved sequence within the H2 subunit of the vaccinia virus entry/fusion complex is important for interaction with the A28 subunit and infectivity. J Virol 82:6244-50
Wagenaar, Timothy R; Ojeda, Suany; Moss, Bernard (2008) Vaccinia virus A56/K2 fusion regulatory protein interacts with the A16 and G9 subunits of the entry fusion complex. J Virol 82:5153-60
Townsley, Alan C; Moss, Bernard (2007) Two distinct low-pH steps promote entry of vaccinia virus. J Virol 81:8613-20
Resch, Wolfgang; Hixson, Kim K; Moore, Ronald J et al. (2007) Protein composition of the vaccinia virus mature virion. Virology 358:233-47
Husain, Matloob; Weisberg, Andrea S; Moss, Bernard (2007) Sequence-independent targeting of transmembrane proteins synthesized within vaccinia virus factories to nascent viral membranes. J Virol 81:2646-55
Wagenaar, Timothy R; Moss, Bernard (2007) Association of vaccinia virus fusion regulatory proteins with the multicomponent entry/fusion complex. J Virol 81:6286-93
Husain, Matloob; Weisberg, Andrea S; Moss, Bernard (2007) Resistance of a vaccinia virus A34R deletion mutant to spontaneous rupture of the outer membrane of progeny virions on the surface of infected cells. Virology 366:424-32
Charity, James C; Katz, Ehud; Moss, Bernard (2007) Amino acid substitutions at multiple sites within the vaccinia virus D13 scaffold protein confer resistance to rifampicin. Virology 359:227-32

Showing the most recent 10 out of 69 publications